Brief: ScPharmaceuticals Inc Announces Receipt Of Written Minutes From Type C Meeting With FDA Regarding Development Of Furoscix

Scpharmaceuticals

01/07/2021 13:13

July 1 (Reuters) - scPharmaceuticals Inc  SCPH.O :
    * SCPHARMACEUTICALS INC. ANNOUNCES RECEIPT OF WRITTEN
MINUTES FROM
TYPE C MEETING WITH THE FDA REGARDING DEVELOPMENT OF FUROSCIX®
    * SCPHARMACEUTICALS INC - FUROSCIX NDA RESUBMISSION TARGETED
FOR
Q4 2021
    * SCPHARMACEUTICALS INC - FDA AND COMPANY IN ALIGNMENT ON
PATH
FORWARD
    * SCPHARMACEUTICALS INC - FDA HAS NOT REQUESTED
MODIFICATIONS TO
DEVICE
    * SCPHARMACEUTICALS - ENDED Q1 OF 2021 WITH CASH,
EQUIVALENTS,
RESTRICTED CASH & INVESTMENTS OF $96.5 MILLION
    * SCPHARMACEUTICALS - BELIEVES CASH, EQUIVALENTS, RESTRICTED
CASH
& INVESTMENTS SUFFICIENT TO FUND OPERATIONS INTO 2023

Source text for Eikon:  ID:nGNX56YqWG 
Further company coverage:  SCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))